Klinisyen Gözüyle COVİD-19 Tedavisi

Year 2020, Volume: 1 Issue: 1, 18 - 23, 30.06.2020

Ersin Günay

Abstract

Yirmi birinci yüzyılın ilk çeyreğinde en önemli sağlık sorunu viral enfeksiyonlar oldu. Bu virüsler içerisinde de Korona virüsler hem 3 kez salgına neden olarak SARS-CoV, MERS-CoV ve COVID-19 hem de pek çok insanın ölümüne yol açarak karşımıza çıkmıştır. Yüksek yayılma hızı ve önemli derecede mortalitesi olan bu viral enfeksiyonun güncel bilgiler ışığında etkinliği güvenilir çalışmalar ile kanıtlanmış bilinen bir tedavisi henüz yoktur. Bundan dolayı, hastalığın tedavisine yönelik acil seçenek olarak tedavi şemalarına giren ve COVİD-19’un tedavisinde etkinliği tam olarak kanıtlanmamış bazı ilaçlar kullanılmaya başlamıştır. Bu ilaçların seçimindeki en önemli sebepler, daha önceki pek çok hastalıkta SARS-CoV, MERS-CoV, HIV enfeksiyonu gibi güvenli kullanımları ve deneysel çalışmalarda nCOV-19 virüsünün yaşam döngüsü üzerinde etkili olabileceğine dair bulgulara ulaşılmış olmasıdır. Bu derlemede, güncel literatür eşliğinde erişkin hastalar için önerilen medikal tedavi seçenekleri, immün plazma tedavisi ve geliştirilmekte olan Korona virüs aşılarından bahsedilecektir.

Keywords

Antiviral tedaviler , Koronavirüs aşısı , İmmün Plazma , Hiperimmünglobülin , SARS-CoV-2 , nCoV-2019

COVID-19 Treatment: From the perspective of the clinician

Abstract

Viral infections have been the most important health problem in the first quarter of the twenty-first century. Among these viruses, Corona viruses have emerged as the most important agents both by causing outbreaks for 3 times SARS-CoV, MERS-CoV and COVID-19 and large number of deaths. In the light of current literature for this viral infection with high spreading rate and significant mortality, there is no known treatment whose effectiveness has been proven with reliable study results. Therefore, some medicines without proven efficacy on COVID-19 have entered the treatment schemes as an emergency option. The most important reasons for the selection of these drugs were their safe use in many previous diseases such as SARS-CoV, MERS-CoV, and HIV infections and evidences in experimental studies that they might have an impact on the life cycle of COVID-19 virus. In this review, we will discuss about medical treatment options, immune plasma treatment, and Corona virus vaccines being developed for adult patients in the light of current literature.

Keywords

Antiviral treatments , Coronavirus vaccine , Immune Plasma , Hyperimmunoglobulin , SARS-CoV-2 , nCoV-2019

References

• Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 COVID-19 . JAMA 2020;323 18 :1824-1836. doi:10.1001/jama.2020.6019
• Bilim Kurulu Çalışması. COVID-19 SARS-CoV-2 enfeksiyonu Rehberi. TC. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü 14 Nisan 2020 Ankara https:// covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf , en son 17 Mayıs 2020’de ulaşılmıştır
• Borba MGS, Val FFA, Sampaio VS. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus SARS-CoV-2 infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial Clorocovid- 19 Study . JAMA Netw Open. 2020; 3:e208857. doi:10.1001/ jamanetworkopen.2020.8857
• Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bio Science Trends 2020;14 : 72-73.
• Mentré F, Taburet AM, Guedj J.Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 2015; 15:150-151.
• Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020. doi:10.1002/ jmv.25729. [published online February 27, 2020].
• Choy KT, Yin-Lam Wong A, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARSCoV-2 replication in vitro. Antiviral Res 2020;104786. doi:10.1016/j.antiviral.2020.104786
• de Wit E, Feldmann F, Cronin J. Prophylactic and therapeutic remdesivir GS- 5734 treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117:6771-6776. doi:10.1073/pnas.1922083117
• Foolad F, Aitken SL, Shigle TL.Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. Clin Infect Dis. 2019;68:1641-1649.
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus 2019- nCoV . Nat Rev Drug Discov. 2020;19:149-150.
• Soo YO, Cheng Y,Wong R. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676-678.
• Horby P, Shen Lim W, Emberson J. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv. 2020; Available at: https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1.
• https://ginasthma.org/covid-19-gina-answers-to-frequently-asked-questions- on-asthma-management/ en son 17 Mayıs 2020’de ulaşılmıştır
• https://goldcopd.org/gold-covid-19-guidance/ en son 17 Mayıs 2020’de ulaşılmıştır
• Xu X, Han M, Li T. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970-10975. doi:10.1073/ pnas.2005615117
• Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398-400.
• Soo YO, Cheng Y,Wong R. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676-678.
• Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015; 4:709.
• Duan K, Liu B, Li C. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117:9490-9496. doi:10.1073/pnas.2004168117
• https://dosyamerkez.saglik.gov.tr/Eklenti/37341,covid-19-immun-konvalesan- plazma-tedarik-ve-klinik-kullanim-rehberi-guncel--r1-v1pdf.pdf?0
• Thanh Le T, Andreadakis Z, Kumar A.The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:305-306. doi:10.1038/d41573-020- 00073-5
• Zhu F, Li Y, Guan X. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020 Published Online May 22, 2020 https://doi.org/10.1016/S0140-6736 20 31208-3
• Ayoub BM. COVID-19 vaccination clinical trials should consider multiple doses of BCG. Pharmazie. 2020;75 4 :159. doi:10.1691/ph.2020.0444
• Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395 10236 :1545-1546. doi:10.1016/S0140-6736 20 31025-4
• Zhang T, Sun L, Feng RE. Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:E040. doi: 10.3760/ cma.j.cn112147-20200311-00312.
• Luo W, Yu H, Gou J, Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia COVID-19 . Preprints. 2020, 2020020407
• Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017; 149:38–44. 13.
• Schmitt FCF, Manolov V, Morgenstern J, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care. 2019; 9:19. 14.
• Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019; 181:77–83
• Cattaneo M, Bertinato EM, Birocchi S. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? [published online ahead of print, 2020 Apr 29]. Thromb Haemost. 2020;10.1055/s-0040-1712097. doi:10.1055/s-0040-1712097
• Bilim Kurulu Çalışması. COVID-19 SARS-CoV-2 enfeksiyonu Erişkin Hasta Tedavisi. TC. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü 19 Haziran 2020 Ankara COVID-19_REHBERI_ERISKIN_HASTA_TEDAVISI.pdf